NCT06980740招募中不适用
Video-Tumorboard PLUS
University Hospital Muenster3 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2025年5月1日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 300
- 试验地点
- 3
- 主要终点
- Presentation of external patients in the video-tumorboard
研究概览
简要总结
In weekly expert meetings for oncological diagnostics and therapy, known as tumor boards, individual therapy recommendations are developed for cancer patients. By further developing and optimizing the CCCs' video tumor boards, initially using skin cancer as an example, we want to ensure that more patients can benefit from the expertise of several specialist disciplines and innovations - regardless of where they live.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The study includes adult, external patients who, according to the certification requirements of the German Cancer Society, should be presented to the CCCs in a tumor board .
- •Inclusion criteria for patients:
- •Minimum age 18 years
- •Consent to participate in the study (signing of patient consent) should be presented in vTB+ according to the doctor, based on the disease/diagnosis, especially in the case of:
- •Malignant melanoma from stage IIB
- •Malignant melanoma and stage shift/recurrence o Extracutaneous melanoma o Cutaneous lymphoma from stage Ib o Problem cases with malignant, epithelial tumors (BCC, SCC) with interdisciplinary issues, e.g. complicated localization, extension/ infiltration (e.g. Ulcus rodens, Ulcus terebrans), metastasized tumors, immunosuppressed patients o all rare malignant skin tumors (including Merkel cell carcinoma, DFSP, MFH, leiomyosarcoma, S., Kaposi's sarcoma, angiosarcoma), regardless of stage o severe side effects from drug-based tumor therapy • is an external patient: An external patient is someone who receives tumor therapy exclusively or in co-treatment in the branch or in an external clinic (in distinction to patients without prior treatment for initial presentation at the CCC) . This also applies to patients who are only seen once at the vTB.
- •In this case, revenue/cost aspects and the DKG requirement are ignored. This means that so-called external patients can also be treated at the center, including initiation of therapy. The decisive factor is the presentation of the external patient (personal presentation of the external patients is not mandatory) and that external co-treaters are consistently informed and involved.
- •Inclusion criteria for external doctors:
- •has a medical license
- •has dermatological patients who are eligible to be presented in the vTB+
排除标准
- •Patients will be excluded from the study if they meet the following criteria:
- •Linguistic or other limitations (such as dementia) that prevent independent consent to the privacy policy.
- •No consent to participate in the study (patient consent) or withdrawal of consent during the course of the study In addition, external physicians will be excluded from the study if no joint cooperation agreement can be negotiated and signed.
结局指标
主要结局
Presentation of external patients in the video-tumorboard
时间窗: Day 365
Increase in the proportion of external patients in the video-tumorboard
次要结局
- Increase in the proportion of external patients invited to a clinical study(Day 365)
- Adherence to tumorboard recommendations for external patients(Up to two weeks after inclusion)
- Offer of supportive therapies by the comprehensive cancer center(Up to two days after inclusion)
- Duration of the transmission of the tumorboard recommendations(Up to two weeks after inclusion)
- "Time to integration" into palliative care(Once per patient within two weeks after transmission of the tumorboard recommendation if applicable)
研究者
研究点 (3)
Loading locations...
相似试验
招募中
不适用
Molecular Tumor Board at the Center for Personalized Medicine TübingenAdvanced CancerNCT03503149University Hospital Tuebingen1,000
已完成
不适用
Intra-procedural 360-degree Display for Performing Percutaneous Liver Tumor AblationPercutaneous Tumor AblationNCT03500757Case Comprehensive Cancer Center11
招募中
不适用
Register study of the Molecular Tumor Board (tumor entity-spanning molecular characterization program to evaluate individualized tumor biology-guided therapy in adults with rare and advanced tumor entities)Cross-tumor entity (adult patients = 18 years of age with any advanced tumor disease or with rare tumor entity (incidence of less than one case per 100,000 population)).N/ADRKS00025847niversitätsklinikum Freiburg Klinik für Innere Medizin I Schwerpunkt Hämatologie, Onkologie und Stammzelltransplantation1,000
尚未招募
不适用
Can interdisciplinary tumor boards for determining the further procedure in patients with urological carcinoma be equivalently replaced by appropriately trained Large Language Models (LLMs)? Results of a multicenter study on the concordance and differences in the recommendations of real tumor boards and virtual LLM tumor boards.DRKS00034797Klinikum St. Elisabeth Straubing100
招募中
不适用
Molecular Tumor Board - A Registry of the East German Hematology and Oncology Study Group.hematologic or oncologic diseasesDRKS00032977Martin-Luther-Universität Halle-Wittenberg250